MET exon 14 skipping mutation

Drug	Drug Name	Drug Description
DB15133	Tepotinib	An oral tyrosine kinase inhibitor targeted against MET for the treatment of metastatic non-small cell lung cancer in patients exhibiting MET exon 14 skipping mutations.

Drug	Drug Name	Target	Type
DB15133	Tepotinib	P-glycoprotein 1	transporter
DB15133	Tepotinib	Cytochrome P450 3A4	enzyme
DB15133	Tepotinib	Cytochrome P450 2C8	enzyme
DB15133	Tepotinib	ATP-binding cassette sub-family G member 2	transporter
DB15133	Tepotinib	Hepatocyte growth factor receptor	target
DB15133	Tepotinib	Nischarin	target
DB15133	Tepotinib	Melatonin receptor type 1B	target
DB15133	Tepotinib	Serum albumin	carrier
DB15133	Tepotinib	Alpha-1-acid glycoprotein 1	carrier
DB15133	Tepotinib	Solute carrier family 22 member 1	transporter
DB15133	Tepotinib	Solute carrier family 22 member 2	transporter
DB15133	Tepotinib	Multidrug and toxin extrusion protein 1	transporter
DB15133	Tepotinib	Multidrug and toxin extrusion protein 2	transporter
DB15133	Tepotinib	Bile salt export pump	transporter
DB15133	Tepotinib	Cytochrome P450 2C9	enzyme

Drug	Drug Name	Phase	Status	Count
DB00958	Carboplatin	2	Recruiting	1
DB01229	Paclitaxel	2	Recruiting	1
DB00642	Pemetrexed	2	Recruiting	1
DB15133	Tepotinib	2	Recruiting	1
DB15043	Toripalimab	2	Recruiting	1